<DOC>
	<DOCNO>NCT00660504</DOCNO>
	<brief_summary>This study drug ( Amrubicin ) believe work stop tumor cell body grow . The purpose study evaluate efficacy safety amrubicin cisplatin compare etoposide-cisplatin first-line treatment extensive disease small cell lung cancer The subject , randomize AP group may involve pharmacokinetic study amrubicin metabolite : amrubicinol voluntarily .</brief_summary>
	<brief_title>Phase3 Study Amrubicin With Cisplatin Versus Etoposide-cisplatin Extensive Disease Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Amrubicin</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>Histologically/cytologically proven small cell lung cancer Extensive disease No prior chemotherapy regimen Age 18 year old ECOG performance status 01 Brain metastasis require treatment Treatment ( Surgical radiotherapy ) primary tumor Interstitial pneumonia pulmonary fibrosis Abnormal cardiac function myocardial infraction within 6 month study enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Extensive Disease-Small Cell Lung Cancer</keyword>
</DOC>